Life-threatening hematomas in COVID-19 patients

Ümit Alakuş, M.D.,¹ Umut Kara, M.D.,² Şebnem Çimen, M.D.,¹ Cantürk Taşçı, M.D.,³ Mehmet Eryılmaz, M.D.¹

¹Department of General Surgery, University of Health Sciences, Gülhane Training and Research Hospital, Ankara-Turkey
²Department of Anesthesiology and Reanimation, University of Health Sciences, Gülhane Training and Research Hospital, Ankara-Turkey
³Department of Pulmonology, University of Health Sciences, Gülhane Training and Research Hospital, Ankara-Turkey

ABSTRACT

BACKGROUND: The COVID-19 pandemic has caused over 1.75 million deaths in the world to date. Although the leading cause of mortality is respiratory disorders and thromboembolic pathologies, other rare pathologies may also increase mortality and morbidity. In our study, we aimed to examine life-threatening hematomas, risk factors, and management during COVID-19.

METHODS: Institutional center (a third level pandemic center) database was searched for patients hospitalized for COVID-19 during 10 months period between March 11, 2020, and December 17, 2020, retrospectively. Patients with bleeding symptoms/signs were detected. Patients with gastrointestinal system bleeding were excluded from the study. Patients with hematomas were included in the study.

RESULTS: Eleven of a total 5484 patients had hematomas (0.2%). Median age was 76 (min–max: 56–90). Seven (63.6%) patients were male and 4 (36.4%) were female. All patients had at least one comorbidity, been under treatment dose of low-molecular-weight heparin (LMWH) and severe or critical COVID-19 disease. Seven retroperitoneal hematomas, two rectus sheath hematomas, one breast hematoma, and in one patient both retroperitoneal and breast hematomas were diagnosed. Angiographic arterial embolization was applied to 5 (45.5%) patients. Overall mortality rate in patients with bleeding complications was 54.5% (n=6), and the male-to-female ratio was 66.7% (n=4) versus 33.3% (n=2).

CONCLUSION: Hematomas are rare, but mortality increasing phenomena in COVID-19 patients. Age, male gender, severe or critical COVID-19 disease, comorbidities, and treatment dose of LMWH may be risk factors. New onset of abdominal/back pain and ecchymotic skin lesions may be signs of bleeding in this patient group. Mortality can be reduced by early diagnosis of hematoma and interventional methods.

Keywords: Bleeding; COVID-19; hematoma.

INTRODUCTION

Fever and respiratory symptoms are prominent in COVID-19 disease. It has also effects on many systems such as gastrointestinal, neurological, genitourinary, and hematological systems. While the majority of critically ill patients with COVID-19 have isolated respiratory failure, often acute respiratory distress syndrome (ARDS) and multiple organ dysfunctions occur in 20–30% of patients with critical illness and more often in fatal cases.¹ Although there are only a few published pathologic reports of patients with COVID-19, histopathology of lung specimens from patients with early disease shows characteristic findings of ARDS and evidence of small-vessel occlusion.²,³ Laboratory and imaging studies found an increased risk of thrombotic complications in patients with COVID infection. Xu et al.⁴ identified a total of 16.67% of mostly critically ill patients with a high risk for thrombotic events, of which 17.3% were diagnosed with deep vein thrombosis. Patients with COVID-19 pneumonia also have a high risk of PE in small branches of pulmonary arteries and arterial thrombosis.⁵,⁶ As thrombotic events have been shown in many studies, low-molecular-weight heparin (LMWH) prophylaxis and its early initiation have been recommended and accepted.⁷ The recommended dose of LMWH is still controversial, but it has
become a standard in COVID-19 treatment. However, during the COVID-19 treatment process, various life-threatening bleeding is also observed. Although the majority of bleeding in COVID-19 patients is seen in the gastrointestinal system, body compartments bleeding with less frequent has also started to be included in the literature as case reports. Scialpi et al.\[8\] had reported the first retroperitoneal hematoma during COVID-19 treatment. Guo et al.\[9\] had reported giant retroperitoneal hematoma during extracorporeal membrane oxygenation (ECMO) in a patient with COVID-19 pneumonia. Bakirov et al.\[10\] described left inferior epigastric artery injury in a COVID-19 patient. Patel et al.\[11\] reported a life-threatening psoas hematoma due to retroperitoneal hemorrhage in a COVID-19 patient on LMWH treated with arterial embolization. Dou and Patel\[12\] found a new palpable breast mass without skin changes in a COVID-19 patient, they performed an aspiration from the mass and reported the case as a hematoma. We have also seen hematomas during COVID-19 treatment in our center. We aimed to evaluate the risk factors, key points to diagnose earlier, and management of less frequent seen bleedings in this study.

MATERIALS AND METHODS

This retrospective study was conducted at Gülhane Training and Research Hospital after obtaining approval from the Ministry of Health of Turkey (December 15, 2020/13_18_18) and Institutional Review Board (2020/Number). Verbal and written consent for the use of the data was obtained from all patients. Patient consent was also obtained for the photograph used.

Institutional database was searched for patients hospitalized for COVID-19 during 10 months period between the day of first COVID-19 case on March 11, 2020, and December 17, 2020, retrospectively. Patients with bleeding symptoms/signs were detected and who had gastrointestinal bleeding were excluded from the study. Patients with hematomas were included in the study.

Demographic and clinical data along with the laboratory parameters of the study subjects were retracted from institutional database. From data, age, gender, comorbidities, coagulation parameters, d-dimer levels, bleeding site, LMWH or other antiagregant-anticoagulant medication, day of treatment before bleeding, transfusion amounts, diagnostic radiological technique and arterial embolization treatment, and length of hospital stay were used in the statistical analysis.

The study was carried out in accordance with the Code of Ethic of the World Medical Association (Declaration of Helsinki) and followed the strengthening the reporting of observational studies in epidemiology (STROBE) guidelines.

Interventional Technique

Angiographic arterial embolization was used as an invasive method in bleeding. Femoral artery was used for catheterization. For rectus sheath hematomas (Fig. 1), the epigastric artery was selectively catheterized and embolization was applied to the inferior epigastric artery. For retroperitoneal hematoma (Fig. 2), lumbar arteries were selectively catheterized and embolization was applied to bleeding branches.

Categorical data were expressed as number (percentage) and continuous data as median (minimum–maximum).

RESULTS

A total of 5484 patients had hospitalized because of COVID-19 disease. Gastrointestinal system bleeding or hematomas were observed in 56 (1%) of them during hospitalization. Hematoma rate was 19% (11 of 56 patients) of all bleeding and these patients were included in the study. Seven (63.6%) of these patients were male and 4 (36.4%) were female. Median age and body mass index were 76 (min–max: 56–90) and 27.5 kg/m² (min–max: 21.60–32.70), respectively. Patients demographic and clinical features are given in Table 1. All of patients had severe (n=3, 27.2%) or critical (n=8; 72.3%) disease according to the World Health Organization COVID-19 disease severity classification.\[13\] and were having treatment dose of LMWH\[14\] and four of them were in intensive care unit (ICU) at the time of bleeding (two patients transferred to ICU after bleeding). LMWH doses were planned according to the Turkish Health Ministry COVID-19 Treatment Guide.\[15\] All of the patients
were required treatment dose of LMWH according to the guide, considering their disease severity and D-dimer levels. LMWH was started to be used with the hospitalization of the patients. It was stopped to be used with bleeding until the bleeding has stopped and the patient was hemodynamically stabilized. All of patients had at least one comorbidity such as diabetes mellitus (DM), coronary artery disease (CAD), chronic obstructive pulmonary disease, chronic renal failure, chronic heart failure, lung cancer, renal cell cancer, chronic myeloid leukemia, and previous cerebrovascular event. Five patients were already using antiaggregant before COVID-19.

Table 2 demonstrates laboratory results of cases at administration time and minimum or maximum levels during bleeding. PTZ/INR, aPTT, and platelet counting were in the normal range for all patients at the admission (Table 2). PTZ, INR, and aPTT levels increased with bleeding, their maximum median levels were 18.3 s (min–max: 11.60–41.50), 1.61 (min–max: 1.11–3.78), and 41.3 s (min–max: 24.90–49.20), respectively. Platelet median level decreased to 138,000×10³ cells/µL (min–max: 35.00–176.00) during bleeding. Admission median hemoglobin and hematocrit levels were 12.7 g/dL (min–max: 7.60–17.40) and 36.2% (min–max: 23.50–52.50), and decreased to 6.5 g/dL (min–max: 1.70–12.50), respectively. Median d-dimer and fibrinogen levels were 1.42 mg/dL (min–max: 0.28–91.00) and 600 mg/dL (min–max: 169.00–900.00) and increased to 12.64 mg/dL (min–max: 0.95–80.00) and 654 mg/dL (min–max: 312.00–900.00), respectively.

Median length of stay before bleeding was 8 days (min–max: 4–26). Median systolic blood pressure at the time of bleeding mean was 94 mmHg (min–max: 74–120).

Back pain, ecchymosis, hypotension, and abdominal pain were the prior symptom and sign during bleeding (Table 1). Asymptomatic one patient was suspected of bleeding because of decreasing hemoglobin, and retroperitoneal hematoma diagnosed. Differential diagnosis of patients revealed seven retroperitoneal hematomas, two rectus sheath hematomas, one breast hematoma, and in one patient both retroperitoneal and breast hematomas. Mobile ultrasound was used for diagnose in five patients and computed tomography angiography for the other six patients. Median number of erythrocyte suspension replacement and fresh frozen plasma was 5 units (min–max: 0.00–17.00) and 2 units (min–max: 0.00–10.00), respectively. Interventional radiological treatment (angioembolization) was applied to 5 (45.5%) of 11 patients with bleeding complications (three retroperitoneal hematomas and two rectus sheath hematomas).

Median length of hospital stay was 16 days (min–max: 8.00–31.00). Overall mortality rate in patients with bleeding complications was 54.5% (n=6 patients), and the male-to-female ratio was 66.7% (n=4) versus 33.3% (n=2). Mortality rate was 40% (n=2) in patients who received interventional
treatment and 66.7% (n=4) in those who did not. Mortality rate was 75% (six of eight) in patients with retroperitoneal bleeding. No mortality was observed in isolated breast and rectus sheath bleeding. Median d-dimer level was 1.5 mg/dL (min–max: 0.28–25.78) in patients with mortality and 1.31 (min–max: 0.48–10.88) in patients without mortality (Table 3).

### DISCUSSION

The COVID-19 pandemic has caused over 1.75 million deaths in the world to date. Although the leading cause of mortality is respiratory disorders and thromboembolic pathologies, other rare pathologies may also increase mortality and morbidity. Spontaneous bleeding to potential gaps is one of these phenomena. The disease and the anticoagulant treatment may induce the bleeding.

The most common cause of retroperitoneal hematomas are trauma- and anticoagulant-induced hematomas. It is classified according to the retroperitoneal zones it develops, and its management is accepted by conservative or surgical methods if required. In addition, with the widespread use of interventional radiology, angioembolization has increasingly replaced surgery. Despite this development, it should always be kept in mind that the surgical option can provide not only the prevention of bleeding but also the treatment of an abdominal compartment syndrome that may develop due to a retroperitoneal hematoma. In our study, none of the patients had abdominal compartment syndrome. Scialpi et al. described the first retroperitoneal hematoma related COVID-19, in a 57-year-old man with a history of non-Hodgkin lymphoma, treated with autologous cell transplantation 1 year ago and later diagnosed with COVID-19 infection at nasopharyngeal swab sample. The patient was having prophylactic dose of LMWH. Scialpi, Guo, Alakuş et al. Life-threatening hematomas in COVID-19 patients

| Patients | Admission Hgb/Min | Admission Hct/Min | Admission Pts/Min | Admission Ptz/Max | Admission INR/Max | Admission APTT/Max | Admission D-Dimer/Max | Admission Fibrinogen/Max |
|----------|-----------------|------------------|------------------|------------------|------------------|-------------------|----------------------|------------------------|
| 1        | 9.3/5.3         | 29.3/17.9        | 110/35           | 18.8/41.5        | 1.65/3.78        | 18.8/47.4         | 4.25/16.9            | 627/1627               |
| 2        | 9.3/5           | 27.7/15          | 162/152          | 12/13.7          | 1.05/1.20        | 35/41.3           | 10.88/51.93          | 652/652                |
| 3        | 17.4/12.5       | 52.5/37.2        | 403/176          | 12/14.1          | 1.01/1.20        | 22.5/24.9         | 0.48/0.95            | 169/312                |
| 4        | 12.9/6.5        | 37.4/19.5        | 78/51            | 12.2/41           | 1.03/3.66        | 20.3/44.3         | 1.58/12.64           | 487/802                |
| 5        | 14.4/6.6        | 39.9/19.4        | 165/140          | 13.7/24.2        | 1.17/2.17        | 32.5/37.8         | 0.28/80              | 479/479                |
| 6        | 12.7/8.4        | 36.2/23.6        | 129/129          | 13.3/13.8        | 1.16/1.20        | 29.5/35.5         | 1.31/2.89            | 900/900                |
| 7        | 7.6/1.7         | 23.5/4.8         | 167/53           | 17.5/19.6        | 1.53/1.72        | 46.1/46.1         | 25.78/80             | 314/314                |
| 8        | 13.2/5.3        | 37.9/15.4        | 240/140          | 11.6/11.6        | 0.97/1.28        | 25.4/29.2         | 1.42/1.42            | 654/654                |
| 9        | 12.2/6.6        | 35.2/19.4        | 205/146          | 13.8/18.3        | 1.61/1.61        | 43.6/43.6         | 0.99/9.41            | 434/893                |
| 10       | 14.8/4.1        | 44.6/12.5        | 198/71           | 16.3/25.6        | 1.43/2.26        | 28.3/49.2         | 1.41/30.47           | 900/900                |
| 11       | 10.2/8.5        | 31.1/26.1        | 188/138          | 11.5/12.7        | 1/1.11           | 28.8/28.8         | 0.91/33.75           | 600/678                |

Hgb: Hemoglobin; Hct: Hematocrit; Pts: Platelet; Ptz: Prothrombin time; INR: International normalization rate.

### Table 3. Laboratory and clinical futures of patients according to mortality

|               | Mortality | Median | Min | Max |
|---------------|-----------|--------|-----|-----|
| Age           | No        | 69     | 56  | 79  |
| BMI           | Ex        | 81     | 75  | 90  |
| Admission D-Dimer mg/dL | No        | 1.41   | 0.48| 10.88|
| Maximum PTZ   | No        | 13.8   | 12.7| 25.6|
| Maximum INR   | No        | 1.2    | 1.11| 2.26|
| Length of hospital stay to the bleeding day | No | 6     | 4   | 20  |
| Replaced ES units | No    | 2      | 0   | 6   |
| Replaced FFP units | No    | 0      | 0   | 4   |

FFP: Fresh frozen plasma; BMI: Body mass index; ES: Erythrocyte suspension; Min: Minimum; Max: Maximum.
and Patel used CT for diagnose and arterial embolization for treatment. In our study, the patients were at an elderly age and had at least one comorbidity. The male-to-female ratio was high. They were all severe or critical COVID-19 patients, all of whom received oxygen therapy and they were using therapeutic doses of LMWH and five patients were also using ASA or clopidogrel daily. The earliest bleeding occurred on the 4th day of treatment in our study. Eight patients had retroperitoneal hematoma, bedside ultrasound was used for diagnosis because of patients were unstable to transport. Other four were diagnosed with CT. Bedside ultrasound may be used hemodynamically unstable patients for diagnose. Arterial embolization was used in three patients in our study.

Rupture of the epigastric vessels was reported to be associated with abdominal wall hematomas. In a study of spontaneous hematomas of the rectus abdominis muscle, the mean patient age was 59 years; the most common symptom was abdominal pain (100%); 93% had an abdominal mass, and 38% had peritoneal irritation findings. Moreover, the most common precipitating factor was found to be cough in 56%. As the patient's bruising and pain were followed by a cough episode, it appeared that abdominal wall hematoma was caused by vigorous contraction of the rectus muscle. Management of abdominal wall hemorrhages may be conservative or interventional radiological angioembolization may be an effective option, if required. Bakirov et al. reported a 75-year-old male COVID-19 patient having therapeutic dose of LMWH with inferior epigastric artery bleeding. The patient undergone arterial embolization. In our study, two rectus sheath hematoma, both treated by arterial embolization.

Duo et al. reported a breast hematoma in a 67-year-old woman with new palpable breast mass in a COVID-19 patient. She was hemodynamically unstable. The patient recovered with conservative treatment. In our study, two breast hematomas observed, one also had retroperitoneal large hematoma and mortality occurred. Other hematoma resolved by conservative treatment. Breast hematomas may not require invasive treatment, but another accompanying focus, such as retroperitoneal bleeding, may be the cause of mortality.

In our study, mortality developed in patients with retroperitoneal hemorrhage requiring relatively more transfusion. It can be thought that this may be due to transfusion reactions added to pulmonary dysfunction due to COVID-19 or even that develop secondary to massive transfusion reactions in some patients. Unfortunately, there is not enough number of patients to reveal this clearly due to limiting factors of the study. The relative rarity of hematomas was the most important limiting factor of our study. The retrospective nature of the study was considered as another important limiting factor.

Conclusion

With utilization of anticoagulation regimens to treat the associated COVID-19 hypercoagulable state, hematomas are important and life-threatening diagnostic considerations when evaluating patients with COVID-19. Age, male gender, severe or higher level COVID-19 disease, elevated d-dimer at hospital admission, comorbidities and antiinflammatory daily usage, and therapeutic dose of LMWH should be risk factors. New-onset abdominal/back pain and ecchymotic skin lesions may be signs of bleeding in this group of patients. Mortality can be reduced with early diagnosis and interventional methods. We think that higher case numbers can be reached and risk factors can be analyzed better with multicenter studies.

Ethics Committee Approval: This study was approved by the Gülhane Scientific Research Ethics Committee (Date: 15.11.2020, Decision No: 13_18_18).

Peer-review: Internally peer-reviewed.

Authorship Contributions: Concept: Ü.A., U.K., Ş.Ç., C.T., M.E.; Design: Ü.A., U.K., Ş.Ç., C.T., M.E.; Supervision: C.T., M.E.; Resource: Ü.A., U.K., Ş.Ç., C.T., M.E.; Materials: Ü.A., U.K., Ş.Ç., C.T., M.E.; Data: Ü.A., U.K., Ş.Ç., C.T., M.E.; Analysis: Ü.A., U.K., Ş.Ç.; Literature search: Ü.A., U.K., C.T., M.E.; Writing: Ü.A., U.K., Ş.Ç., C.T., M.E.; Critical revision: Ü.A., U.K., Ş.Ç., C.T., M.E.

Conflict of Interest: None declared.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81. [CrossRef]
2. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700–4. [CrossRef]
3. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420–2. [CrossRef]
4. Xu JF, Wang L, Zhao L, Li F, Liu J, Zhang L, et al. Risk Assessment of Venous Thromboembolism and Bleeding in COVID-19 Patients; 2020.
5. Chen J, Wang X, Zhang S, Liu B, Wu X, Wang Y, et al. Findings of acute pulmonary embolism in COVID-19 patients. SSRN Electron J 2020.
6. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382:e28. [CrossRef]
7. Miesbach W, Makris M, COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost 2020;26:1076029620938149. [CrossRef]
8. Scialpi M, Russo P, Plane E, Gallo E, Scalera GB. First case of retroperitoneal hematoma in COVID-19. Turk J Urol 2020;46:407–9. [CrossRef]
9. Guo SH, Zhu SM, Yao YX. Giant retroperitoneal hematoma during extracorporeal membrane oxygenation in a patient with coronavirus disease-2019 pneumonia. J Cardiothorac Vasc Anesth 2020;34:2839–40.
10. Bakirov I, Bakirova G, Albalawi Y, Asiri AY, Faqihi F, Bakirli I, et al. Left inferior epigastric artery injury in COVID-19 patient. Case report and literature review. Int J Surg Case Rep 2020;76:415–20. [CrossRef]
11. Patel I, Akoluk A, Douedi S, Upadhyaya V, Costanzo E, et al. Life-threatening psoas hematoma due to retroperitoneal hemorrhage in a COVID-19 patient on enoxaparin treated with arterial embolization: A case report. J Clin Med Res 2020;12:458–61. [CrossRef]
12. Dou E, Patel H. New palpable breast mass in a COVID-19 patient. J Breast Imaging 2020;2:513–4. [CrossRef]
13. World Health Organization. Clinical Management of COVID-19: Interim Guidance, 27 May 2020. Geneva: World Health Organization; 2020. Bakanlıği TS. COVID-19 (SARS-CoV2 Enfeksiyonu) Rehberi; 2020. Müdürlüğü TCSBHSG. COVID-19 (SARS-CoV-2 Enfeksiyonu) Antisitokin-Antiinflamatuar Tedaviler, Koagülopati Yönetimi; 2020. Available from: https://covid19.saglik.gov.tr/Eklenti/39296/0/covid-19rehberiantisitokin-antiinflamatuartedavilerkoagulopatiyonetimipdf.pdf
14. Altun H, Sarı S, Aydın İ, Karahan İ, Akdağ M, Alimoğlu O. Retropertioneal hematoma. Ulus Travma Acil Cerrah Derg 1996;2:173–9.
15. Çolakoğlu MK, Özdemir A, Kalcın S, Demir A, Demiral G, Pergel A. Spontaneous abdomen and abdominal wall hematomas due to anticoagulant/antiplatelet use: Surgeons’ perspective in a single center. Ulus Travma Acil Cerrah Derg 2020;26:50–4. [CrossRef]
16. Abu-zidan FM, Jawas A, Boraite M, Ahmed MU. Delayed retroperitoneal bleeding causing acute abdominal compartment syndrome: Case report. Ulus Travma Acil Cerrah Derg 2011;17:183–5. [CrossRef]
17. Ergün N, Çevik AA, Holliman CJ, Manisalı M, İnan F, Samsy T. Conservative treatment of giant abdominal wall hematoma. Ulus Travma Acil Cerrahi Derg 2004;10:141–4.
18. Sihler KC, Napolitano LM. Complications of massive transfusion. Chest 2010;137:209–20. [CrossRef]